The National Health Care Institute values cooperation with other agencies and stakeholders to expand our knowledge, share our own expertise, divide workload or to stand stronger together. We collaborate with a wide range of international stakeholders in platforms, projects and initiatives.
The National Health Care Institute collaborates with HTA agencies from Belgium, Ireland, Austria and Luxembourg in the Beneluxa initiative. This collaboration aims for sustainable access to and appropriate use of medicines, to ensure timely access and affordability of medicines for all patients. In order to achieve this, the collaboration anticipates on national health challenges effectively by having early insight in new pharmaceutical products and in new indications of existing products coming to the market (Horizon Scanning). It also tries to increase the efficiency of the assessment, pricing and reimbursement of medicines by exchanging expertise and by mutual recognition of Health Technology Assessments. The participating countries share policy expertise and best practices. They improve the payers’ position in the market by improving their knowledge on products, usage and markets and by joint (price) negotiations for specific products. Lastly, the collaboration aims to improve transparency on pricing between the collaborating countries. The initiative is divided into four taskforces: Horizon Scanning, Information sharing and policy exchange, Health Technology Assessment and Pricing & Reimbursement. The National Health Care Institute participates in all four taskforces.
EUnetHTA was established to support collaboration between European HTA organisations and brings benefit to healthcare systems at the European, national, and regional level. By creating an effective and sustainable network for HTA across Europe, this collaboration helped with developing reliable, timely, transparent, and transferable information to contribute to HTA in European countries. The National Health Care Institute was one of the members of this network and had an active role in the collaboration as we are involved in the development of substantive deliverables. EUnetHTA JointAction 3 ended in May 2021 and was succeeded by EUnetHTA21, a temporary two-year project that is an important next step for the network. It will build on the achievements and lessons learned from the previous EUnetHTA Joint Actions. This project focusses on supporting a future EU HTA system and the National Health Care Institute leads the EUnetHTA21 consortium.
International Horizon Scanning Initiative (IHSI)
The International Horizon Scanning Initiative (IHSI) provides data that empower political decision-makers, HTA agencies and payer organizations to drive for better pricing in medicinal products. IHSI data enables healthcare systems to prepare for disruptive technologies through data insights that deliver the leverage required to confidently assess new products coming to market. The National Health Care Institute participates in this initiative and is the chair of the Executive Committee.
The Heads of Agencies Group (HAG)
The Heads of Agencies Group (HAG) is a newly constructed network set up by the heads of 19 European HTA agencies. The HAG is an HTA-focused collaborative network for high-level strategic exchange and discussion. It has a focus on supporting the development of the basis for joint work on all HTA activities at EU level, within the model of EU cooperation anticipated by the Regulation on HTA. It also supports the joint work performed at the technical and scientific level by HTA bodies across Europe. And it supports the preparation of national systems and capacities for the adoption of the HTA Regulation. It also aims to advise policy makers and relevant EU and national institutions on matters regarding HTA, particularly cooperation in HTA. The National Health Care Institute participates in this network and has set up the secretariat that will support this collaboration.
HTx is a Horizon 2020 project supported by the European Union, kicking-off in January 2019 and lasting for 5 years. The main aim of HTx is to create a framework for the Next Generation Health Technology Assessment (HTA) to support patient-centered, societally oriented, real-time decision-making on access to and reimbursement for health technologies throughout Europe. The National Health Care Institute actively participates in the work packages that make up the HTx project and also contributes to the workshops that are given to other HTx members.
European Social Insurance Platform (ESIP)
The National Health Care Institute is member of ESIP (European Social Insurance Platform). ESIP is a strategic platform that gathers over 50 national social security organisations insuring citizens in 17 Member States and Switzerland. ESIP covers various branches of social insurance including health, pensions, family and social inclusion, disability and rehabilitation and unemployment. The platform has been set up for transnational dialogue and exchange of best practices between national social security institutions in Europe. It also functions as a strategic network for developing common positions to influence the European decision-making process and acts as a consultation forum for the European institutions and other multinational bodies active in the field of social security.
Medicine Evaluation Committee (MEDEV)
The National Health Care Institute is co-chair of the Medicine Evaluation Committee (MEDEV). MEDEV represents an informal cooperation between 22 national authorities from 18 Member States and Switzerland responsible for the assessment, pricing and reimbursement of medicines in Europe. MEDEV members include national HTA agencies and social health insurers (payers). The overarching mission of MEDEV is to further the sustainable provision of medicines to patients who are publicly insured. MEDEV provides an informal platform for exchanges between national bodies responsible for the assessment, pricing and reimbursement of medicines to support them in their role at national level. It also provides a platform for consultation at EU level, offering specific expertise in areas such as pricing and reimbursement of pharmaceuticals and policy advice and analysis.